The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics

Khatib, Sami El; Salla, Mohamed

doi:10.1016/j.lrr.2022.100335

Cited by 5 publications

(4 citation statements)

References 190 publications

(168 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[40,41] These advancements above, fortified by an expanding interdisciplinary approach, not only accelerate the discovery and production of antibody mimetics but also augment their applicability in a wide array of scientific domains (Table 2), illustrating the potential for antibody mimetics to replace outdated antibody-based drugs or revitalize obsolete ones and positioning antibody mimetics on a trajectory toward dominance in the coming years. Nevertheless, concerns about offtarget effects and toxicity necessitate careful evaluation, [42] with each case requiring extensive reassessment of the safety profile before reintroduction into the market.…”

Section: Discussionmentioning

confidence: 99%

Antibody mimetics: The next generation antibody engineering, a retrospective and prospective analysis

Zhang,

Wu,

Dang

2023

Biotechnology Journal

View full text Add to dashboard Cite

Antibody mimetics represent the fourth generation of antibody engineering, following polyclonal antibodies, monoclonal antibodies, and genetically engineered antibody fragments. Despite cumulative studies highlighting the advantages of antibody mimetics, including enhanced recognition properties, superior affinity, stability, penetrability, and cost‐effectiveness, a comprehensive review of this evolving field is notably absent. In this study, spanning 1986–2023 and analyzing 24,318 publications, we undertake a retrospective and prospective analysis to elucidate the evolution roadmap of antibody mimetics, providing insights into the current landscape, global contributions, and future trajectories. Concurrently, our aim is to establish standardized terminology and delineate the research scope within the realm of antibody mimetics. These endeavors not only chart the trajectory and scope of antibody mimetics research but also underscore its potential to revolutionize medicine, technology, and science.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibody mimetics: The next generation antibody engineering, a retrospective and prospective analysis

Zhang,

Wu,

Dang

2023

Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…They may not have the same efficacy as traditional antibodies, particularly in complex biological systems. Additionally, their potential for off-target effects and toxicity may need to be carefully evaluated (Khatib & Salla, 2022 ). Moreover, the antibody mimetic engineering still requires sophisticated design and complicated biopanning process, which also lead to high cost and limits its application and commercialization.…”

Section: Discussionmentioning

confidence: 99%

Antibody mimetics: the next generation antibody engineering, a retrospective and prospective analysis

Dang,

Zhang,

2023

Preprint

View full text Add to dashboard Cite

Antibody mimetics is a novel antibody engineering approach after the development of polyclonal, monoclonal antibodies, and genetically engineered antibody fragments. Inspired by the structure and function of natural antibodies, antibody mimetics offer many advantages over conventional antibodies and can be constructed by protein-directed evolution, peptide design and synthesis, or fusion of complementarity-determining regions through intervening framework regions. A series of parent protein/peptide structures and technical roadmaps have been established to induce better recognising properties, superior affinity, stability, penetrability, and cost-effectiveness of the designed mimetics. This article aims to summarise the evolution of antibody mimetics engineering, illustrate the highlights and hotpots in this research field using scientometric analysis, and give an anticipatory analysis on this increasing research topic.

show abstract

“…Antibodies have two functional domains, namely Fab and Fc. Each antibody has two Fab domains and one Fc domain [21] . CDRs in Fab are responsible for antigen binding, and CDRH3 is crucial for antibody-antigen interaction.…”

Section: Overview Of Antibody Generative Modelsmentioning

confidence: 99%

A comprehensive overview of recent advances in generative models for antibodies

Meng,

Zhou,

et al. 2024

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics

Cited by 5 publications

References 190 publications

Antibody mimetics: The next generation antibody engineering, a retrospective and prospective analysis

Antibody mimetics: The next generation antibody engineering, a retrospective and prospective analysis

Antibody mimetics: the next generation antibody engineering, a retrospective and prospective analysis

A comprehensive overview of recent advances in generative models for antibodies

Contact Info

Product

Resources

About